exocrine pancreatic insufficiency epi therapeutics diagnostics Industry Size, Share & Growth Forecast 2033

exocrine pancreatic insufficiency epi therapeutics diagnostics by Production Analysis, by Consumption Analysis, by Import Market Analysis (Value & Volume), by Export Market Analysis (Value & Volume), by Price Trend Analysis Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

exocrine pancreatic insufficiency epi therapeutics diagnostics Market Overview

The exocrine pancreatic insufficiency (EPI) therapeutics diagnostics market refers to the industry focused on diagnosing and treating EPI, a condition where the pancreas fails to produce sufficient digestive enzymes. As the global exocrine pancreatic insufficiency EPI therapeutics diagnostics market size is estimated to be around $1.4 billion, the growth outlook and market forecast indicate a promising expansion, driven by increasing awareness and advancements in diagnostic technologies, with the industry expansion expected to be fueled by the rising prevalence of EPI and the growing demand for effective diagnostic and therapeutic solutions.

Loading chart…

The exocrine pancreatic insufficiency EPI therapeutics diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period, driven by macro drivers such as the increasing prevalence of EPI, advancements in diagnostic technologies, and rising awareness about the condition. Key forces shaping the industry include technology shifts towards non-invasive diagnostic tests, regulations supporting the development of novel therapies, and consumer behavior driving the demand for effective treatments. The largest region in the market is North America, while the fastest-growing region is Asia-Pacific, driven by the growing healthcare infrastructure and increasing awareness about EPI.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	8.95 million
Growth rate	CAGR of 8.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	AbbVie; Allergan; Nordmark Arzneimittel; Digestive Care; Janssen Pharmaceuticals; Cilian; Anthera Pharmaceuticals; AzurRx Biopharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The exocrine pancreatic insufficiency epi therapeutics diagnostics market is expected to witness significant growth, driven by increasing awareness and advancements in diagnostic technologies. The market dynamics are shaped by various factors, including growth drivers, restraints, opportunities, and challenges, which are crucial for understanding the exocrine pancreatic insufficiency epi therapeutics diagnostics market size and growth forecast.

Growth Drivers2 items

Advances in diagnostic technologies, such as non-invasive testing and biomarker-based diagnostics, are driving the growth of the exocrine pancreatic insufficiency epi therapeutics diagnostics market by enabling early and accurate diagnosis.

Increasing prevalence of exocrine pancreatic insufficiency (EPI) and growing awareness about the condition among healthcare professionals and patients are fueling the demand for effective diagnostic solutions, contributing to the market's growth forecast.

Restraints2 items

High costs associated with diagnostic tests and therapies, as well as limited reimbursement coverage, are restraining the growth of the exocrine pancreatic insufficiency epi therapeutics diagnostics market, particularly in developing regions.

Stringent regulatory requirements and the need for extensive clinical trials are slowing down the approval and launch of new diagnostic products, affecting the exocrine pancreatic insufficiency epi therapeutics diagnostics market size.

Opportunities2 items

Emerging markets, such as Asia-Pacific and Latin America, offer significant opportunities for growth due to increasing healthcare expenditure and improving healthcare infrastructure, driving the exocrine pancreatic insufficiency epi therapeutics diagnostics market forward.

Collaborations and partnerships between diagnostic companies, research institutions, and healthcare providers can facilitate the development of innovative diagnostic solutions and enhance the growth forecast of the exocrine pancreatic insufficiency epi therapeutics diagnostics market.

Challenges2 items

The exocrine pancreatic insufficiency epi therapeutics diagnostics market faces challenges related to the complexity of EPI diagnosis, which requires specialized expertise and equipment, limiting access to diagnostic services in resource-constrained settings.

The need for ongoing education and training of healthcare professionals to ensure accurate diagnosis and effective management of EPI patients poses a significant challenge, affecting the overall exocrine pancreatic insufficiency epi therapeutics diagnostics market size and growth forecast.

Market Segmentation

Loading chart…

The exocrine pancreatic insufficiency epi therapeutics diagnostics market can be segmented based on application, which plays a crucial role in determining the overall market size. This segmentation is essential for understanding the exocrine pancreatic insufficiency epi therapeutics diagnostics segmentation and its impact on the market. The application segment includes various subtypes, each contributing to the market size in distinct ways.

The application segment of the exocrine pancreatic insufficiency epi therapeutics diagnostics market includes diagnosis and treatment of exocrine pancreatic insufficiency. This segment is critical in the market taxonomy as it directly affects the demand for therapeutics and diagnostics. Understanding this segment is vital for industry stakeholders to develop effective strategies and products that cater to the specific needs of patients with exocrine pancreatic insufficiency.

Regional Insights

Loading chart…

The exocrine pancreatic insufficiency epi therapeutics diagnostics market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of advanced diagnostic technologies and rising investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high policies supporting research and development, and a large patient population. In Europe, drivers include a strong infrastructure, favorable demographics, and significant investments in medical research. Asia Pacific is driven by a growing ecosystem, increasing adoption of digital health technologies, and large-scale government investments in healthcare. Latin America and Middle East & Africa are expected to be driven by improving infrastructure, rising adoption of diagnostic technologies, and growing demographics.

The regional forecast indicates that North America will continue to dominate the market, while Asia Pacific will experience the highest exocrine pancreatic insufficiency epi therapeutics diagnostics market growth. Understanding these regional trends is crucial for stakeholders to develop effective strategies and capitalize on emerging opportunities in the global market.

Competitive Landscape

The exocrine pancreatic insufficiency epi therapeutics diagnostics market is moderately consolidated, driven by a mix of global players and local companies. The competitive landscape is shaped by key levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Companies operating in this space must navigate the complex exocrine pancreatic insufficiency epi therapeutics diagnostics competitive landscape, where differentiation and strategic positioning are crucial for success.

Common strategies among key players include mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization. Companies seek to differentiate themselves through technology, service models, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are notable for their strategic focus:

AbbVie: regional expansion

Allergan: premium pricing

Nordmark Arzneimittel: innovation pipeline

Digestive Care: local manufacturing

Janssen Pharmaceuticals: OEM tie-ups

Cilian: vertical integration

Key exocrine pancreatic insufficiency epi therapeutics diagnostics Companies8 items

AbbVie

Allergan

Nordmark Arzneimittel

Digestive Care

Janssen Pharmaceuticals

Cilian

Anthera Pharmaceuticals

AzurRx Biopharma

Market Ecosystem

The exocrine pancreatic insufficiency epi therapeutics diagnostics ecosystem spans upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of diagnostic products and services, ultimately reaching patients with exocrine pancreatic insufficiency. The ecosystem's boundaries are defined by the interactions between these segments, from raw material suppliers to end users.

Raw material suppliers — provide diagnostic reagents

Technology providers — develop diagnostic platforms

OEMs / manufacturers — produce diagnostic equipment

System integrators / EPCs — integrate diagnostic systems

Distributors / channel partners — distribute diagnostic products

Service providers / after-sales — offer maintenance and support

Regulators/standards bodies — establish diagnostic standards

In the exocrine pancreatic insufficiency epi therapeutics diagnostics ecosystem, control points are held by regulators and standards bodies, who influence adoption through approvals and standards. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact product development and distribution. Switching costs and partnerships also play a role, as companies may be locked into specific technologies or suppliers, and interoperability requirements can affect the integration of diagnostic systems. Furthermore, the ecosystem may differ by region due to varying regulatory frameworks and market conditions, highlighting the need for a nuanced understanding of the exocrine pancreatic insufficiency epi therapeutics diagnostics ecosystem through a thorough value chain analysis.

Recent Industry Insights

The exocrine pancreatic insufficiency epi therapeutics diagnostics industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships, such as collaborations between pharmaceutical companies and diagnostic firms, have been formed to enhance the diagnosis and treatment of exocrine pancreatic insufficiency. Furthermore, there have been key mergers and acquisitions, with major players expanding their product portfolios and strengthening their presence in the market.

Recent product launches, including innovative diagnostic kits and point-of-care testing devices, have improved the accuracy and accessibility of exocrine pancreatic insufficiency diagnosis. Additionally, regulatory changes have supported the approval of new therapeutics, driving growth in the exocrine pancreatic insufficiency epi therapeutics diagnostics market. These advancements have been fueled by funding rounds and expansions, underscoring the industry's potential for continued innovation and expansion.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the exocrine pancreatic insufficiency epi therapeutics diagnostics market. The market attractiveness is moderate, driven by increasing awareness and diagnosis rates. The competitive intensity is high, with several key players vying for market share. Looking at the exocrine pancreatic insufficiency epi therapeutics diagnostics market outlook, the long-term prospects are promising, with a growing demand for innovative diagnostic solutions. The innovation landscape is evolving, with advancements in testing technologies and personalized medicine. However, the demand-supply balance is a concern, with a shortage of skilled professionals and limited access to diagnostic facilities in some regions. Key risk factors include regulatory changes, reimbursement issues, and the need for standardized diagnostic protocols.

11 items

1. Executive Summary

2. exocrine pancreatic insufficiency epi therapeutics diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market by: Regions (Value)

8. Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Competition by Key Manufacturers

8.1. Global exocrine pancreatic insufficiency epi therapeutics diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global exocrine pancreatic insufficiency epi therapeutics diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Allergan

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Nordmark Arzneimittel

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Digestive Care

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Janssen Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cilian

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Anthera Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AzurRx Biopharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market

Figure 4: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Drivers

Figure 5: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Challenges

Figure 6: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Trends

Figure 7: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Opportunity

Figure 8: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Restraint

Figure 9: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Porter's Five Forces

Figure 10: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Value (USD Million) By Region

Figure 11: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Value (USD Million) By Region

Figure 15: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

39 items

Table 1: Market Segmentation Analysis

Table 2: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Value (USD Million) By Region

Table 4: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: AbbVie Basic Information And Sales Area

Table 15: AbbVie. Products Portfolio

Table 16: Allergan Basic Information And Sales Area

Table 17: Allergan. Products Portfolio

Table 18: Nordmark Arzneimittel Basic Information And Sales Area

Table 19: Nordmark Arzneimittel. Products Portfolio

Table 20: Digestive Care Basic Information And Sales Area

Table 21: Digestive Care. Products Portfolio

Table 22: Janssen Pharmaceuticals Basic Information And Sales Area

Table 23: Janssen Pharmaceuticals. Products Portfolio

Table 24: Cilian Basic Information And Sales Area

Table 25: Cilian. Products Portfolio

Table 26: Anthera Pharmaceuticals Basic Information And Sales Area

Table 27: Anthera Pharmaceuticals. Products Portfolio

Table 28: AzurRx Biopharma Basic Information And Sales Area

Table 29: AzurRx Biopharma. Products Portfolio

Table 30: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Value (USD Million) By Region

Table 31: Global exocrine pancreatic insufficiency epi therapeutics diagnostics Market Share (%) By Region (2025-2032)

Table 32: North America Market Value (USD Million) (2025-2032) By Country

Table 33: Europe Market Value (USD Million) (2025-2032) By Country

Table 34: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 35: South America Market Value (USD Million) (2025-2032) By Country

Table 36: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 37: Research Programs/Design For This Report

Table 38: Key Data Information From Secondary Sources

Table 39: Key Data Information From Primary Sources

FAQs

1. What is the current exocrine pancreatic insufficiency epi therapeutics diagnostics market size?

The current market size is approximately USD 1.2 billion as of 2023.

2. What is the expected growth forecast for the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

3. What are the key drivers of the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

Increasing prevalence of pancreatic disorders and advancements in diagnostic technologies drive the market.

4. What are the major challenges facing the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

High costs of diagnostic tests and lack of awareness about exocrine pancreatic insufficiency are major challenges.

5. Which regions are expected to lead the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

North America and Europe are expected to dominate the market due to high prevalence of pancreatic disorders.

6. Who are the top companies in the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

Top companies include Abbott Laboratories, Siemens Healthcare, and Roche Diagnostics.

7. What future opportunities exist in the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

Emerging markets and development of non-invasive diagnostic tests present future opportunities.

8. How will technology impact the exocrine pancreatic insufficiency epi therapeutics diagnostics market future outlook?

Advances in technologies like genetic testing and biomarker discovery will drive market growth.

9. What is the current regulatory landscape for the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

Regulatory bodies like FDA and EMA play a crucial role in approving diagnostic tests and therapies.

10. How will the exocrine pancreatic insufficiency epi therapeutics diagnostics market size change in the next 5 years?

The market is expected to reach USD 1.8 billion by 2028, driven by increasing demand for diagnostic tests.

Contact for Full Report

Loading report content...

exocrine pancreatic insufficiency epi therapeutics diagnostics Industry Size, Share & Growth Forecast 2033

Market Snapshot

exocrine pancreatic insufficiency epi therapeutics diagnostics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current exocrine pancreatic insufficiency epi therapeutics diagnostics market size?

2. What is the expected growth forecast for the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

3. What are the key drivers of the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

4. What are the major challenges facing the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

5. Which regions are expected to lead the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

6. Who are the top companies in the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

7. What future opportunities exist in the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

8. How will technology impact the exocrine pancreatic insufficiency epi therapeutics diagnostics market future outlook?

9. What is the current regulatory landscape for the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

10. How will the exocrine pancreatic insufficiency epi therapeutics diagnostics market size change in the next 5 years?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

exocrine pancreatic insufficiency epi therapeutics diagnostics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current exocrine pancreatic insufficiency epi therapeutics diagnostics market size?

2. What is the expected growth forecast for the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

3. What are the key drivers of the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

4. What are the major challenges facing the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

5. Which regions are expected to lead the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

6. Who are the top companies in the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

7. What future opportunities exist in the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

8. How will technology impact the exocrine pancreatic insufficiency epi therapeutics diagnostics market future outlook?

9. What is the current regulatory landscape for the exocrine pancreatic insufficiency epi therapeutics diagnostics market?

10. How will the exocrine pancreatic insufficiency epi therapeutics diagnostics market size change in the next 5 years?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation